LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Selumetinib | 0.37 | uM | LJP6 | 72 | hr | 1476 | 3715 | 3694 | 1.0058 | 1.0096 |
| SK-BR-3 | Sirolimus | 0.37 | uM | LJP6 | 72 | hr | 1476 | 2196 | 3694 | 0.5945 | 0.3244 |
| SK-BR-3 | Sorafenib | 0.37 | uM | LJP6 | 72 | hr | 1476 | 3427 | 3694 | 0.9278 | 0.8797 |
| SK-BR-3 | SU11274 | 0.37 | uM | LJP5 | 72 | hr | 1476 | 4224 | 3694 | 1.1435 | 1.2390 |
| SK-BR-3 | Fedratinib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 3521 | 3694 | 0.9533 | 0.9223 |
| SK-BR-3 | TGX221 | 0.37 | uM | LJP5 | 72 | hr | 1476 | 3457 | 3694 | 0.9358 | 0.8931 |
| SK-BR-3 | Torin1 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 1427 | 3694 | 0.3865 | -0.0221 |
| SK-BR-3 | Torin2 | 0.37 | uM | LJP5 | 72 | hr | 1476 | 1255 | 3694 | 0.3397 | -0.1000 |
| SK-BR-3 | Tozasertib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 1236 | 3694 | 0.3348 | -0.1083 |
| SK-BR-3 | Trametinib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 2543 | 3694 | 0.6885 | 0.4810 |
| SK-BR-3 | TWS119 | 0.37 | uM | LJP5 | 72 | hr | 1476 | 3796 | 3694 | 1.0278 | 1.0463 |
| SK-BR-3 | Vemurafenib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 3877 | 3694 | 1.0495 | 1.0825 |
| SK-BR-3 | Withaferin A | 0.37 | uM | LJP5 | 72 | hr | 1476 | 1592 | 3694 | 0.4311 | 0.0521 |
| SK-BR-3 | Withaferin A | 0.37 | uM | LJP6 | 72 | hr | 1476 | 1417 | 3694 | 0.3838 | -0.0266 |
| SK-BR-3 | WYE-125132 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 1538 | 3694 | 0.4164 | 0.0278 |
| SK-BR-3 | WZ3105 | 0.37 | uM | LJP5 | 72 | hr | 1476 | 1182 | 3694 | 0.3200 | -0.1329 |
| SK-BR-3 | XMD11-50 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 2620 | 3694 | 0.7093 | 0.5158 |
| SK-BR-3 | Y39983 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 3113 | 3694 | 0.8427 | 0.7380 |
| SK-BR-3 | YM 201636 | 0.37 | uM | LJP5 | 72 | hr | 1476 | 3667 | 3694 | 0.9927 | 0.9878 |
| SK-BR-3 | ZSTK474 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 1877 | 3694 | 0.5082 | 0.1807 |
| SK-BR-3 | Afatinib | 1.11 | uM | LJP6 | 72 | hr | 1476 | 1506 | 3694 | 0.4077 | 0.0132 |
| SK-BR-3 | Sigma A6730 | 1.11 | uM | LJP5 | 72 | hr | 1476 | 2618 | 3694 | 0.7087 | 0.5147 |
| SK-BR-3 | Alvocidib | 1.11 | uM | LJP6 | 72 | hr | 1476 | 981 | 3694 | 0.2656 | -0.2236 |
| SK-BR-3 | AT-7519 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 1152 | 3694 | 0.3120 | -0.1462 |
| SK-BR-3 | AZD 5438 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 1387 | 3694 | 0.3757 | -0.0402 |